Lymphoid malignancies


Lymphoid malignancies are cancers that originate from lymphocytes, immune system cells. These malignancies include non-Hodgkin lymphoma, Hodgkin lymphoma, myeloma and lymphocytic leukemias. We draw your attention to three significant presentations that were given during the EHA24 congress. Philippe Moreau during the plenary session addressed the current therapies, available treatment options and new strategies for patients with multiple myeloma. In her oral session about fixed-duration treatment with venetoclax plus obinutuzumab, Kirsten Fischer discussed trial results on progression-free survival (PFS) and minimal residual disease (MRD)-negativity in CLL patients. Finally in the science-in-focus session, Steve Baylin focused on epigenomic changes and their significance in risk scenarios for initiation and progression of cancers.

Links to the library and multimedia

Click on the blocks below to read the full stories, view abstracts, presentations, webcasts and expert interviews.

Philippe Moreau | New treatment strategies in multiple myeloma

Stephen Baylin | Epigenomic changes mediating leading risk scenarios for initiation and progression of cancers. Implications for prevention, interception and therapy

Iñaki Martin-Subero | The role of epigenomics to diagnose and estimate prognosis in lymphoid neoplasms

Iñaki Martin-Subero | The role of epigenomics to diagnose and estimate prognosis in lymphoid neoplasms

Kirsten Fischer | Fixed-duration venetoclax plus obinutuzumab improves progression-free survival and minimal residual disease negativity in patients with previously untreated CLL and comorbidities

Shai Izraeli | Opportunities and challenges of personalized approaches in HR ALL

Irene Ghobrial | The bone marrow niche in plasma cell disorders

Malwine Pogodzinski | Transient subclones carrying NT5C2 mutations define a high-risk patient group with poor outcome in pediatric relapsed b-cell precursor acute lymphoblastic leukemia

Sabina Chiaretti | A dasatinib-blinatumomab combination for the front-line treatment of adult ph+ all patients. Preliminary results of the gimema lal2116 d-alba trial; on behalf of gimema acute leukemia working party

Laura Hinze | Genome-wide crispr-cas9 screen reveals synthetic lethality of wnt pathway activation and asparaginase in drug-resistant acute leukemias

Lesley-Ann Sutton | Mechanisms of resistance to novel agents in chronic lymphocytic leukemia

Ulrich Jäger | CAR T cells for lymphoma / ALL

Anita Rijneveld | BCR-ABL-like ALL

Florence Cymbalista | Sequencing therapy for relapsed/refractory CLL

M Mohty | CAR T in Acute leukemia

Stefania Oliva | MRD in MM

Eva Domingo-Domènech | Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical hodgkin lymphoma: 2-year extended follow-up from cohort d of the phase 2 checkmate 205 study

Irene Roberts | Neonatal leukemia